Table III.
Receptor | Ligand | Delivery System | Type of nucleic acid | Key results | Reference | |
---|---|---|---|---|---|---|
Macrophages | ||||||
Mannose receptor | Mannose | PLL polyplexes | DNA | Transfection to monocyte-derived macrophages using Man-PLL polyplexes | [151] | |
Mannose |
PLL polyplexes and pAsp(DET) polyplexes |
DNA | 8× increased transfection efficacy for Man-PLL polyplexes, 500× increased transfection efficacy for Man-pAsp(DET) polyplexes in murine bone marrow derived macrophages | [152] | ||
CM Mannose | Direct conjugate | siRNA | Ligand-dependent gene silencing in monocyte-derived macrophages (in vitro) and in splenic and liver macrophages (in vivo) | [61] | ||
Mannose | Cationic nano-hydrogel | siRNA | Receptor-dependent delivery of siRNA to M2 macrophages and efficient gene knockdown in primary cells and in mice | [153, 154] | ||
Dendritic cells | ||||||
Mannose receptor | Mannose | PEI polyplexes | pDNA | Increase of transfection efficacy by mannosylation of PEI polyplexes, uptake was reduced in presence of the inhibitor Mannose-BSA | [82] | |
Mannose | PEGylated LNPs | mRNA | Variation of PEG-spacer length (PEG100, PEG1000 and PEG2000) was evaluated; LNPs with Man-PEG1000 showed highest transfection efficacy | [156] | ||
CMM | Direct conjugate | siRNA | Ligand-dependent gene silencing activity in monocyte derived DCs | [61] | ||
Mannan | LNP | Self-amplifying RNA | Enhanced immunization was observed for LNPs decorated with multivalent mannose residues | [157] | ||
DEC205 | Anti-DEC205 scFv | LNP | siRNA | DEC205-dependency on uptake was demonstrated; targeted LNPs showed twofold increase in uptake compared to untargeted LNPs and LNPs with an isotype of scFv | [160] | |
T-lymphocytes | ||||||
CD3 T-cell receptor | Anti-CD3 antibodies | PLL polyplexes | pDNA | 1000-fold enhanced gene expression compared to unmodified PLL and Tf-PLL in T-cells; successful transfection to primary human lymphocytes | [58] | |
CD4 | Anti-CD4 mAb | LNP | siRNA | Specific delivery to CD4+ cells ex vivo; gene silencing activity was observed in blood, bone marrow, spleen and lymph nodes | [59] | |
Ly6c | Anti-Ly6-mAb | LNP | mmRNA | Targeted delivery to Ly6c positive cells in vitro; in vivo evaluation in IBD mouse model showed increased protein expression [20-fold in intestine, tenfold in spleen]; expression of anti-inflammatory IL-10 after delivery of IL-10 encoding mmRNA | [164, 165] | |
n.a | None (chemical targeting) | LNP | Barcode siRNA, sgRNA |
Screening of 168 different LNP formulations in vivo with variations of head group, lipid alkyl chains, phospholipid and molar composition; adamantyl-DSPC delivered siRNA and sgRNA to T cells (and Kupffer cells) |
[166] | |
n.a | None (chemical targeting) | LNP | siRNA | Variation of head group and alkyl chain; piperazine headgroup led to accumulation and gene silencing in the spleen | [167] | |
Integrin β7 | Anti-β7-mAb | LNP | siRNA | CD45 mRNA silencing in CD4+ and CD8+ T cells in spleen and lymph nodes | [167] |
Abbreviations: PLL, Poly-L-lysine; Man, Mannose; pAsp(DET) poly(N-[N-[2-aminoethyl]-2-aminoethyl] aspartamide); CM Mannose, chemically modified mannose; PEI, polyethylene imine; BSA, bovine serum albumin; DCs, dendritic cells; scFv, single chain antibody; CD, cluster of differentiation; Tf, Transferrin; mAb, monoclonal antibody; Ly6c, lymphocyte antigen 6 complex; mmRNA, modified messenger RNA; IBD, inflammatory bowel disease; mAb, monoclonal antibody